Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South America Chronic Inflammatory Demyelinating Polyneuropathy Market

ID: MRFR/HC/51240-HCR
200 Pages
Rahul Gotadki
Last Updated: February 06, 2026

South America Chronic Inflammatory Demyelinating Polyneuropathy Market Research Report By Diagnosis Type (Electromyography, Nerve Conduction Studies, Lumbar Puncture), By Treatment Type (Immunosuppressive Therapy, Intravenous Immunoglobulin, Plasmapheresis, Corticosteroids), By Distribution Channel (Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics), By End User (Hospitals, Research Institutions, Homecare Settings) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South America Chronic Inflammatory Demyelinating Polyneuropathy Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Treatment Type (USD Million)
  49.     4.1.1 Immunotherapy
  50.     4.1.2 Plasmapheresis
  51.     4.1.3 Corticosteroids
  52.     4.1.4 Intravenous Immunoglobulin
  53.     4.1.5 Physical Therapy
  54.   4.2 Healthcare, BY Patient Demographics (USD Million)
  55.     4.2.1 Age Group
  56.     4.2.2 Gender
  57.     4.2.3 Socioeconomic Status
  58.     4.2.4 Geographic Distribution
  59.     4.2.5 Comorbidities
  60.   4.3 Healthcare, BY Healthcare Setting (USD Million)
  61.     4.3.1 Hospitals
  62.     4.3.2 Outpatient Clinics
  63.     4.3.3 Rehabilitation Centers
  64.     4.3.4 Home Healthcare
  65.     4.3.5 Specialized Neurology Centers
  66. 5 SECTION V: COMPETITIVE ANALYSIS
  67.   5.1 Competitive Landscape
  68.     5.1.1 Overview
  69.     5.1.2 Competitive Analysis
  70.     5.1.3 Market share Analysis
  71.     5.1.4 Major Growth Strategy in the Healthcare
  72.     5.1.5 Competitive Benchmarking
  73.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  74.     5.1.7 Key developments and growth strategies
  75.       5.1.7.1 New Product Launch/Service Deployment
  76.       5.1.7.2 Merger & Acquisitions
  77.       5.1.7.3 Joint Ventures
  78.     5.1.8 Major Players Financial Matrix
  79.       5.1.8.1 Sales and Operating Income
  80.       5.1.8.2 Major Players R&D Expenditure. 2023
  81.   5.2 Company Profiles
  82.     5.2.1 Roche (CH)
  83.       5.2.1.1 Financial Overview
  84.       5.2.1.2 Products Offered
  85.       5.2.1.3 Key Developments
  86.       5.2.1.4 SWOT Analysis
  87.       5.2.1.5 Key Strategies
  88.     5.2.2 Novartis (CH)
  89.       5.2.2.1 Financial Overview
  90.       5.2.2.2 Products Offered
  91.       5.2.2.3 Key Developments
  92.       5.2.2.4 SWOT Analysis
  93.       5.2.2.5 Key Strategies
  94.     5.2.3 Sanofi (FR)
  95.       5.2.3.1 Financial Overview
  96.       5.2.3.2 Products Offered
  97.       5.2.3.3 Key Developments
  98.       5.2.3.4 SWOT Analysis
  99.       5.2.3.5 Key Strategies
  100.     5.2.4 Bristol-Myers Squibb (US)
  101.       5.2.4.1 Financial Overview
  102.       5.2.4.2 Products Offered
  103.       5.2.4.3 Key Developments
  104.       5.2.4.4 SWOT Analysis
  105.       5.2.4.5 Key Strategies
  106.     5.2.5 Teva Pharmaceutical Industries (IL)
  107.       5.2.5.1 Financial Overview
  108.       5.2.5.2 Products Offered
  109.       5.2.5.3 Key Developments
  110.       5.2.5.4 SWOT Analysis
  111.       5.2.5.5 Key Strategies
  112.     5.2.6 Mylan (US)
  113.       5.2.6.1 Financial Overview
  114.       5.2.6.2 Products Offered
  115.       5.2.6.3 Key Developments
  116.       5.2.6.4 SWOT Analysis
  117.       5.2.6.5 Key Strategies
  118.     5.2.7 Pfizer (US)
  119.       5.2.7.1 Financial Overview
  120.       5.2.7.2 Products Offered
  121.       5.2.7.3 Key Developments
  122.       5.2.7.4 SWOT Analysis
  123.       5.2.7.5 Key Strategies
  124.     5.2.8 AstraZeneca (GB)
  125.       5.2.8.1 Financial Overview
  126.       5.2.8.2 Products Offered
  127.       5.2.8.3 Key Developments
  128.       5.2.8.4 SWOT Analysis
  129.       5.2.8.5 Key Strategies
  130.     5.2.9 Merck & Co. (US)
  131.       5.2.9.1 Financial Overview
  132.       5.2.9.2 Products Offered
  133.       5.2.9.3 Key Developments
  134.       5.2.9.4 SWOT Analysis
  135.       5.2.9.5 Key Strategies
  136.   5.3 Appendix
  137.     5.3.1 References
  138.     5.3.2 Related Reports
  139. 6 LIST OF FIGURES
  140.   6.1 MARKET SYNOPSIS
  141.   6.2 SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
  142.   6.3 SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  143.   6.4 SOUTH AMERICA MARKET ANALYSIS BY HEALTHCARE SETTING
  144.   6.5 KEY BUYING CRITERIA OF HEALTHCARE
  145.   6.6 RESEARCH PROCESS OF MRFR
  146.   6.7 DRO ANALYSIS OF HEALTHCARE
  147.   6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  148.   6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  149.   6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
  150.   6.11 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
  151.   6.12 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
  152.   6.13 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
  153.   6.14 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
  154.   6.15 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
  155.   6.16 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
  156.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  157. 7 LIST OF TABLES
  158.   7.1 LIST OF ASSUMPTIONS
  159.     7.1.1
  160.   7.2 South America MARKET SIZE ESTIMATES; FORECAST
  161.     7.2.1 BY TREATMENT TYPE, 2026-2035 (USD Million)
  162.     7.2.2 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  163.     7.2.3 BY HEALTHCARE SETTING, 2026-2035 (USD Million)
  164.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  165.     7.3.1
  166.   7.4 ACQUISITION/PARTNERSHIP
  167.     7.4.1

South America Healthcare Market Segmentation

Healthcare By Treatment Type (USD Million, 2022-2035)

  • Immunotherapy
  • Plasmapheresis
  • Corticosteroids
  • Intravenous Immunoglobulin
  • Physical Therapy

Healthcare By Patient Demographics (USD Million, 2022-2035)

  • Age Group
  • Gender
  • Socioeconomic Status
  • Geographic Distribution
  • Comorbidities

Healthcare By Healthcare Setting (USD Million, 2022-2035)

  • Hospitals
  • Outpatient Clinics
  • Rehabilitation Centers
  • Home Healthcare
  • Specialized Neurology Centers

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions